Regulus Therapeutics (NASDAQ:RGLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other brokerages have also commented on RGLS. Leerink Partners restated a “market perform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. Wells Fargo & Company restated an “equal weight” rating and set a $9.00 price target on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Canaccord Genuity Group reiterated a “hold” rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, Jones Trading reiterated a “hold” rating and issued a $7.00 target price (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.50.

Regulus Therapeutics Stock Up 0.3%

Shares of RGLS opened at $7.87 on Friday. The company’s fifty day moving average is $3.41 and its 200-day moving average is $2.10. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $8.20. The firm has a market cap of $544.87 million, a price-to-earnings ratio of -7.36 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.14. As a group, research analysts predict that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RGLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Regulus Therapeutics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 1,644 shares during the last quarter. PEAK6 LLC acquired a new stake in Regulus Therapeutics in the 4th quarter worth $95,000. Oppenheimer & Co. Inc. acquired a new stake in Regulus Therapeutics in the 1st quarter worth $96,000. Velan Capital Investment Management LP acquired a new stake in Regulus Therapeutics in the 4th quarter worth $111,000. Finally, AQR Capital Management LLC acquired a new stake in Regulus Therapeutics in the 1st quarter worth $120,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.